Insmed (INSM) Status Update summary

Commercial transformation and market expansion

• Target patient population expected to grow from 30,000 to over 2.5 million by 2030, driven by new indications and steady launches.

• Three synergistic programs—TPIP, ARIKAYCE, and brensocatib—each have positive clinical data and blockbuster or multi-blockbuster potential.

• Indications closest to market face little or no competition, enhancing commercial prospects.

• Commercial infrastructure and relationships have been built over years, positioning for rapid launches and efficient market penetration.

• All three therapies have potential to be first- or best-in-disease if approved.

Clinical and commercial updates for key assets

• TPIP showed positive safety and efficacy in PH-ILD and promising blinded data in PAH, with peak sales potential over $2 billion.

• ARIKAYCE demonstrated strong efficacy in MAC lung disease, with 2024 revenue guidance of $340–$360 million and potential to exceed $1 billion in peak sales with label expansion.

• Brensocatib exceeded expectations in the ASPEN study for bronchiectasis, showing reduced exacerbations, improved lung function, and a safety profile comparable to placebo.

• Brensocatib’s peak sales estimate for bronchiectasis alone is now $5 billion, up from prior guidance, with additional upside from undiagnosed populations.

• Each program targets multiple indications, including pulmonary hypertension, MAC lung disease, bronchiectasis, CRSSNP, and HS.

Market access, pricing, and launch strategy

• Brensocatib’s U.S. launch price is expected between $40,000 and $96,000 per year, reflecting strong ASPEN data and safety profile.

• First-in-disease products are expected to capture at least a third of the addressable market, with potential for higher penetration.

• Extensive payer education and early engagement have been conducted, with over 85% of U.S. patient lives already covered in discussions.

• Expansion of the sales force and field teams is underway, with 120+ new hires to support upcoming launches.

• 80% of surveyed U.S. physicians likely to prescribe brensocatib.